Qiagen NV
$ 42.65
-2.74%
11 Aug - close price
- Market Cap 9,054,806,000 USD
- Current Price $ 42.65
- High / Low $ 43.46 / 42.60
- Stock P/E 22.60
- Book Value 16.15
- EPS 1.94
- Next Earning Report -
- Dividend Per Share $0.36
- Dividend Yield 0.86 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 54.44
- 52 Week Low 30.63
About
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Analyst Target Price
$45.78
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-04 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-31 | 2024-04-29 | 2024-02-06 | 2023-10-30 |
| Reported EPS | 0.62 | 0.54 | 0.62 | 0.64 | 0.63 | 0.58 | 0.64 | 0.62 | 0.6 | 0.5 | 0.6 | 0.56 |
| Estimated EPS | 0.6 | 0.54 | 0.62 | 0.62 | 0.63 | 0.54 | 0.65 | 0.59 | 0.56 | 0.47 | 0.6 | 0.54 |
| Surprise | 0.02 | 0 | 0 | 0.02 | 0 | 0.04 | -0.01 | 0.03 | 0.04 | 0.03 | 0 | 0.02 |
| Surprise Percentage | 3.3333% | 0% | 0% | 3.2258% | 0% | 7.4074% | -1.5385% | 5.0847% | 7.1429% | 6.383% | 0% | 3.7037% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Jan 1970 | Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|
| Payment Date | 2026-07-14 | None | 2025-07-10 | None | None |
| Amount | $0.35 | $2.29 | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QGEN
2026-08-10 19:41:04
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM on August 7, 2026. The announcement details Goldman Sachs Group Inc.'s holdings in QIAGEN N.V., including various types of shares and financial instruments, and specifies both real and potential voting rights and capital interests. Goldman Sachs' total capital interest and voting rights stand at 2.63%.
2026-08-10 08:13:32
Deutsche Bank has reiterated its "Buy" rating on Qiagen N.V. stock, with analyst Jan Koch advising clients to purchase the shares. This follows earlier news from August 6th where Jefferies also reiterated its "Buy" rating for Qiagen N.V. The company recently reported strong Q2 2026 results, with adjusted earnings and revenue rising and exceeding analyst expectations, though guidance remains unchanged.
2026-08-09 08:39:30
The Manufacturers Life Insurance Company recently acquired 63,219 shares of Qiagen N.V. (NYSE:QGEN) worth approximately $2.52 million. This purchase is part of broader institutional investment, with various firms like Boston Partners, Norges Bank, and Price T Rowe Associates also holding significant stakes, bringing total institutional ownership to 70%. Despite this, analysts maintain a "Hold" rating for QGEN with an average price target of $43.34, even though the company surpassed recent quarterly earnings and revenue expectations and increased its annual dividend.
2026-08-08 07:40:52
QIAGEN N.V. (NYSE: QGEN) reported Q2 2026 net sales of $535.04 million and net income of $103.401 million, with diluted EPS of $0.50. The company executed a $496.7 million synthetic share repurchase in January 2026, reducing outstanding shares by 5.0%, and approved a $0.35 per share cash dividend for 2026. Operating cash flows for the first half of 2026 were $301.319 million, consistent with the prior year.
2026-08-08 07:40:52
QIAGEN N.V. has released a voting rights announcement per Article 40, Section 1 of the WpHG, following a notification from the AFM. The notification details that The Vanguard Group holds 2.92% of QIAGEN N.V.'s capital and voting rights as of July 30, 2026, corresponding to 6,045,368 ordinary shares. QIAGEN N.V. clarifies that it is not responsible for the accuracy of the notification, which was sourced from the AFM's public register.
2026-08-07 23:39:39
Qiagen N.V.'s average price target has been increased from $43.87 to $44.52 by 17 analysts, suggesting a 7% potential upside based on its closing price. The consensus rating remains a "Buy" from 22 covering analysts. Investors can explore more price target data and analyst recommendations on TradingView.
